Search Results
Results found for "Helen Su"
- High-Content Screening for GPCR Programs: Overcoming Assay Limitations with Fluorescent Ligands
The resulting multiparametric datasets are well-suited for GPCR research, where receptor trafficking, For GPCR assay developers, HCS supports:Â Quantitative visualization of receptor internalization and Assay Design and Pilot Optimization Successful HCS begins with a clearly defined biological question Probe panelsâsuch as lysosomal dyes or cytoskeletal markersâcan be integrated to support multiplexed At Celtarys, we remain committed to enabling this transition and supporting researchers as they design
- The Hidden Burn: How Internal Misalignment Drains Your Biotechâs Runway
Scientific progress doesnât guarantee startup success; strategic clarity does. By the time it surfaces, youâve lost two months of budget and alignment. 2ď¸âŁ Milestone redefinition Most biotech founders donât suffer from having the wrong people. They suffer because everyone has a different idea of what their role actually is.  And suddenly, it becomes obvious what to kill and what to scale. â Thatâs the power of strategic realignment
- How a Failed Experiment Created a Powerful GPCR Imaging Tool
Watch Episode #177 The Experiment That Was Never Meant to Succeed When David Hodsonâs lab teamed up with visualization tool Impact: Â Shared widely â now used globally to map GPCR activity in live systems The success peripheral contributions to metabolic therapy Guide how next-generation incretin drugs are designed Support
- From Farm Fields to GPCR Discovery, GLP-1 and GIP
Surgery electives meant long nights, constant patient responsibilities, and unpredictable call schedules For Hodson, one sustained curiosity thread involved a protein released by alpha cells in the pancreas Suddenly, the puzzle snapped into place. A long-running side project became a central insight.
- Decoding Schild Analysis: The Pharmacologistâs Lens on Competitive Antagonism
Others show subtle curvature or slope deviations. It âs a screening tool, not a substitute for rigorous Schild validation. Common revelations include: Mixtures of receptor subtypes  producing hybrid response patterns.
- How Schild Analysis Protects Your Conclusions in GPCR Research
Catch subtle mechanistic drift. Â GPCR is a nonprofit organization , and Premium Membership directly supports our mission to make reliable University content, and an integrated view of publications, events, insights, and opportunities designed to support
- How GPCR Collaboration Built an Innovation Engine
programs This design had a strategic effect : talent density increased, but so did interdisciplinary surface Suddenly, we could do experiments that individual labs just couldnât afford. But luck alone doesnât sustain an ecosystem.
- From Pipettes to Platforms: The Evolution of GPCR Research
Suddenly, questions that were too risky or expensive to ask in the âmanual eraâ became accessible. Today, success depends less on manual precision and more on experimental design, data interpretation,
- How GPCR Spatial Signaling Sparked a Scientific Journey
It was supposed to be just a summer projectâroutine pipetting, repetitive assays, a box to tick before Yet that summer research placement cracked open a new reality: the thrill of asking questions no one She moved from âWhat am I supposed to do?â to âWhat happens if I try this?â It might be quiet, subtleâan idea you canât stop thinking about. Pay attention to that. For young scientists, that summer moment is waiting.
- Molecular creativity in drug discovery
Upcoming events: Â Global GPCR summits and pharmacology forums shaping 2026 priorities. spatial GPCR signaling shifts discoveryâand how leadership, mentorship, and vision shape translational success GPCR evolved from a grassroots effort to a global force in GPCR scienceâone rooted in connection, sustainability
- Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery
Opium, for example, was used for dysentery and relief of suffering as early as the 3rd century BC; its Diuretic action discovered in sulfanilamide derivatives led to furosemide; sedative effects of early What matters now is not the category , but the fit: Does the chemical matter support the therapeutic Subscribers gain weekly lectures led by Dr. next decade trying to understand. 40 years of expertise at your fingertips: Explore the full library ⤠Subscribe
- A Note from Yamina: Building the Next Chapter of Dr. GPCR
This year, we focused on building for sustainability  â strengthening operations, expanding partnerships GPCR stronger, more connected, and more capable of supporting our growing community. Weâre continuing to seek new strategic partners  who share our goal of supporting the GPCR community GPCR is evolving â thoughtfully, inclusively, and sustainably.
- GPCR Collaboration: From Models to Medicine
Suddenly, computational shortcuts werenât enough. In his view, collaboration is not a bonus or an optional supplementâit is the only way GPCR drug discovery Supporting them is a medicinal chemist who can design and synthesize new scaffolds when commercial libraries If docking can suggest binding modes but canât resolve nanomolar potency differences, they say so. Biased signaling, allosteric binding sites, and subtype selectivity mean there is rarely a straight line
- Predicting GPCR Function: Inside the Carlsson Labâs Modeling Toolbox
such as differentiating agonists from antagonists, predicting biased agonism, or achieving receptor subtype For Carlsson, a prediction is only valid if it survives wet-lab testing. Â If a method canât resolve subtle potency differences, the team prefers to acknowledge that limitation But success depends on researchers who can manage expectations, build trust, and integrate across disciplines
- Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal
A well-behaved molecule in a dish can fail spectacularly in vivo, leaving teams with years of sunk costs How CRO Communication Impacts GPCR Drug Development Success Even the best science falters without operational For scientists in discovery, this means two things: Technical clarity drives survival. Subscribe to The Kenakin Brief  today â¤
- Enhancing GPCR Research Outreach | Dr GPCR University early-bird registration ends soon!
Logo Contest : Let your creativity shine by submitting your design for the Logo Contest before August AbbVie Completes Acquisition of Cerevel Therapeutics Nxera Pharma attended the Drug Discovery Ecosystem Summit
- From Failed Experiments to Predictive GPCR Models
When he first began working in a lab, success seemed elusive: experiments often failed, and bench work A summer spent purifying proteins highlighted his discomfort at the bench. His introduction came through a practical suggestion: explore a new protein family that was gaining traction This success was a revelationâit was possible not only to interpret experimental data but to forecast He believes genuine interestânot trends or external validationâis what sustains long-term scientific
- Irreversible Drugs, Real Control: Design for Durable Target Engagement
framework to predict duration, penetration, and PK/PD separationâso decisions move faster and risks surface Breakthroughs this week:  nanomedicines targeting PAR2 for sustained analgesia; Emerging Voices in GPCR Upcoming events:  Membrane-mimetic screening; GPCR Forum 2025; GPCR-TDD Summit Europe. If your team is designing covalent or tight-binding candidates, these principles reduce surprises and đď¸ Weekly research, careers & event intelligence đ¤ Members-only networking, AMAs & matchmaking đĄ Support
- Innovative Data-Driven Solutions: The pHSense Revolution
Watch Episode 174 You never forget the day your data surprises youâin a positive way. For Dr. Eric Trinquet, that moment arrived when his team successfully tracked GPCR internalization in native This success was not mere luck. Itâs a subtle yet powerful innovation. These were not mere vendor-supplier relationships.
- Transformative GPCR Insights: Unleash New Horizons in Science | Sep 9 - 15, 2024
27, 2024 | 1st Virtual GPCR Forum Conference November 26 - 28, 2024 | GPCRs-Targeted Drug Discovery Summit
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
27, 2024 | 1st Virtual GPCR Forum Conference November 26 - 28, 2024 | GPCRs-Targeted Drug Discovery Summit Precursor Cells Derived from Patients Diagnosed with Schizophrenia Sphingosine 1-phosphate receptor subtype
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
This is the silent advantage of many successful drugs: they bind tightly or covalently , making target But it also means new liability surfaces : persistent effects canât be simply âwashed outâ when things Subscribe to The Kenakin Brief  today â¤
- New Tools, Smart Signals, and The Kenakin Brief
You can already explore the platform and subscribe to The Kenakin Briefâour new newsletter packed with MOR-positive allosteric modulator (BMS-986122) selectively enhances opioid signaling  through specific GÎą subtypes
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
the mindset that helped shape products used across biotech and academiaâand why play, failure, and surprise This mindset, he argues, suffocates innovation. He knows the cost firsthand. For Early-Career Scientists: Donât confuse âfinal productâ with overnight success.
- Understanding Enzyme Inhibition In GPCR Discovery Programs
If you want your molecules to survive first contact with biology, enzyme inhibition must be part of your Breakthroughs this week:  Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology Whether youâre designing a ligand, optimizing ADME, or predicting PK, enzyme inhibition defines what survives Whether youâre building assays or a scientific career, this is a must-read on why risk, surprise, and Read the Feature ⤠Summer Days: Appetite, Suntans, and GPCR Micro-Domains Two recent papers connect ciliary
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
Enzymes decide who survives. to clinical success. Their broad substrate tolerance shields us from xenobiotics. isnât a checkbox; itâs a survival test. Subscribe to The Kenakin Brief  today â¤
- Assay Volume Control: Your GPCR Drug Discovery Power Lever
unlocks a simple lever that separates signal from storytelling, moving programs forward with fewer surprises discovery Flexible , on-demand lessons for busy scientists Influence  the curriculum with your topic suggestions đď¸ Weekly research, careers & event intelligence đ¤ Members-only networking, AMAs & matchmaking đĄ Support
- The Truth About GPCR Product Launches: Years in the Making
Built to Fail, Built to Win: The IP One Gamble After the success of their cAMP assay, Trinquetâs team on the front lines of GPCR science, itâs a new lens to see whatâs always been thereâjust below the surface
- Assay Sensitivity: The Hidden Lever Driving GPCR Drug Discovery
For drug hunters working at the GPCR interface, the difference between a successful lead and a dead-end Better Predictions For drug discovery scientists, time and predictive accuracy are the currency of success pipeline translates directly into better prioritization, cleaner data packages, and fewer late-stage surprises Unlock Assay Volume Control Only in Terryâs Corner đŹ Watch Course Trailers Not sure yet? Subscribe to The Kenakin Brief  today â¤
- Orthosteric vs Allosteric Interactionsâ and the pHSense Shift in Internalization
Breakthroughs this week: New work clarifies how active-state GPCR conformations can support coupling GPCR internalization and soluble proteins; core meetings from GPCR Forum to Biophysics; plus targeted summits That subtle distinction opened the door to a brand-new assay format. For GPCRs, fluorescent ligands have quietly become one of the most versatile technologiesâsupporting Subtype specificity: Â selectively track receptor subtypes in complex brain tissue.





























